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We report results of a clinical exploratory human trial involving 10 participants using a com-
bination of a fluorescent ligand and a laser scanning device, SAPPHIRE System, as an
aid in the diagnosis of Probable Alzheimer’s disease (AD). To the best of our knowledge,
this is the first time that such a technique has been used in vivo of a human lens. The
primary goal of the clinical trial, in addition to safety assessment, was to evaluate efficacy
of the system. By detecting specific fluorescent signature of ligand bound beta amyloid in
the supranucleus (SN) region of the human lens, a twofold differentiation factor between
AD patients and Control groups is achieved. Data from our studies indicates that deeper
regions of the SN provide the highest measures of ligand bound fluorescence signal from
both controls and patients with AD. In addition, we present preclinical studies that were
performed to investigate the binding affinity of the ligand to beta amyloid and evaluate
the pharmacokinetics of the ligand in rabbit eyes. Further studies are underway involving
a larger population for statistical evaluation of the method.
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INTRODUCTION
Alzheimer’s disease (AD) is the leading neurodegenerative disor-
der in the world today and accounts for approximately two-thirds
of cases of dementia. Globally, it affects around 10% of people
above the age of 65. In the United States alone, approximately
five million people suffer from AD-related dementia (Brookmeyer
et al., 2011) with annual associated costs estimated in the range of
$183 billion (Alzheimer’s Association, 2011). Definite diagnosis of
AD is performed post mortem through histopathological identi-
fication of characteristic features including beta-amyloid plaques.
Currently, AD is a clinical diagnosis based on NINCDS-ADRDA
and DSM-IV criteria (McKhann et al., 1984, 2011; Hyman et al.,
2012). The major features are late onset progressive impairment
of short term memory associated with deterioration of language
and visuospatial functions in the absence of disturbance of con-
sciousness and systemic disorders (Esteban-Santillan et al., 1998;
Erkinjuntti and Rockwood, 2003).
According to the amyloid cascade hypothesis, the accumula-
tion of β-amyloid (Aβ) deposits as amyloid plaques in the patient’s
brain is the primary event in the pathogenesis of AD (Hardy and
Selkoe, 2002; Jack et al., 2010; Karran et al., 2011; Reiman et al.,
2012). A post mortem diagnosis of AD is based on the presence of
extracellular neuritic plaques positive for Aβ protein, dystrophic
neurites, and intracellular NFTs in the brain. Amyloidal plaques
are composed of 40–42 amino acid Aβ-folded peptides (McKhann
et al., 2011; Hyman et al., 2012). Incidental AD-like pathology can
be found in cognitively normal individuals over the age of 75,
but large deposits of Aβ suggest active AD (Hardy and Selkoe,
2002). In addition, recent studies demonstrated that functional
and structural brain imaging changes are consistent with Aβ1–42
overproduction, in young adult PSEN1E280A mutation carriers
(Karran et al., 2011; Reiman et al., 2012). Draft guidelines issued
in 2011 by the Alzheimer’s Association and NIA (Alzheimer’s Asso-
ciation, 2011) recommend the incorporation of Aβ biomarkers in
the diagnosis of AD for research purposes.
Presently, there is a major effort investigating the possibility
of diagnosing AD by detecting the presence and accumulation of
protein Aβ. Technologies such as positron emission tomography
(PET) imaging (Klunk et al., 2004; Nordberg, 2004; Doraiswamy
et al., 2012), magnetic resonance (MR) microscopy (Hintersteiner
et al., 2005), and optical imaging (Yang et al., 2012) have been
demonstrated as potential tools to enable detection of amyloid
plaques in living AD patients and animal models. In particular,
florbetapir, which is a radioactive tracer, was recently approved by
the U.S. Food and Drug Administration for PET imaging of the
brain to estimate beta-amyloid plaque density in patients who are
being evaluated for cognitive impairment (Nakada et al., 2008).
However, most of these techniques have some limitations in reso-
lution and are costly. There is a clear need for a technology capable
of improving the diagnosis of AD with high resolution sensitivity
and specificity that offers ease of use during the testing and that
will reasonably priced.
Current studies have been focused on detecting beta-amyloid
in the eye as a technique to aid in the diagnosis of AD in humans
(Goldstein et al., 2003; Moncaster et al., 2010; Koronyo-Hamaoui
et al., 2011) and animal models (Koronyo et al., 2012; Parnell
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et al., 2012). Frederikse (2000) showed lens protein β-sheet arrays
are organized in an amyloid protein supramolecular order in the
interior fiber cells of mammalian ocular lens. Also, Goldstein et al.
(2003) demonstrated the presence of Aβ deposits in the supranu-
cleus (SN) of the lens of the eye in a population in whom AD had
been confirmed by autopsy and differentiated from control sam-
ples. Further studies showing similar results have been extended
to subjects with Down syndrome (Moncaster et al., 2010).
In this paper, we report the results of a clinical exploratory study
involving 10 participants, 5 AD patients and 5 Control, performed
with SAPPHIRE System, which is a combination of a fluorescent
ligand, named Compound #11, and a laser scanning device, to
aid in the diagnosis of probable AD in patients by detecting the
presence of beta-amyloid in the eye of human beings who have
symptoms and signs consistent with Alzheimer’s type dementia.
Measurements were performed on three different locations in the
SN of the eye and show that deeper regions (thickness of 900µm)
show higher level of ligand bound to Aβ. Further clinical stud-
ies with a larger population are being performed for statistical
validation of the system.
MATERIALS AND METHODS
FLUORESCENT LIGAND
Compound #11 is a new fluorescent compound that was designed
according to the molecular rotor motif, which has been shown
to bind to the aggregated Aβ peptide (Sutharsan et al., 2010)
(Figure 1).
Compound #11, whose chemical name is (E)-2-[2-(2-
methoxyethoxy)ethoxy]ethyl-2-cyano-3-[6-(piperidin-1-yl)naph
thalene-2-yl]acrylate is formulated at 0.5% into an ophthalmic
Ointment consisting of 80% petrolatum and 19.5% mineral oil
for topical application.
Fluorescence characterization of the ligand in buffer solution
shows a large Stokes shift, the difference between the emission and
the excitation peaks, of∼90 nm and FWHF of 80 nm when excited
at 470 nm (Figure 2).
OPHTHALMIC OINTMENT PREPARATION
The Ophthalmic Ointment was manufactured by Bio-Concept
Laboratories, Salem, NH in compliance with the current good
manufacturing practices (cGMP) as set forth in the Code of Fed-
eral Regulations, Section 21 parts 210 and 211. The suspension was
first compounded, filled into 1 mL syringes, sterilized by e-beam
irradiation, and then sealed in foil pouched.
LASER SCANNING DEVICE
The laser scanning device is designed to measure emitted fluo-
rescence signal of Compound #11 bound to Aβ aggregates in the
supranuclear region of the lens, the region of interest (ROI). The
device comprises of fluorescence lifetime technique that is based
on short pulse excitation repetitively and recording the subsequent
fluorescence light emission as a function of time. In particular,
time domain fluorescence lifetime spectroscopy has been demon-
strated as a powerful tool to enable separation of fluorophores
based on their lifetime signatures (Lakowicz, 2006; Koberling et al.,
2007). In our application, the fluorescence lifetime decay rate is
registered for each location scanned in the human lens and thus
FIGURE 1 | Chemical structure of Compound #11.
FIGURE 2 | Emission spectrum (585 nm) of Compound #11 (excitation
470 nm).
an extra dimension of the fluorophores distributions can be eval-
uated and analyzed based on both fluorescence decay rate and the
increase in fluorescence intensity upon binding to Aβ aggregates
as mentioned earlier.
The optical scanner device itself comprises of a pico-second
pulsed laser (PicoQuant, Berlin) with a peak wavelength at 470 nm,
pulse width 200 ps, 40 MHz repetition rate, and average output
power of 4µW. Fluorescence from excited molecules is collected
in epi-fluorescence configuration, filtered with dichroic mirrors
(Semrock Inc.) and an additional bandpass filter (centered at
585 nm) to reject remaining scattered laser light, and passed
through an aperture to enable confocal detection. The detector
is a single photon avalanche diode (MPD, Bolzano, Italy) with
50 ps FWHM timing resolution and efficiency of 50% at 550 nm.
IN VITRO CHARACTERIZATION
Aggregated Aβ peptides preparation
Aggregated Aβ peptide was prepared by dissolving Aβ(1-42) in
PBS pH 7.4 to a final concentration of 100µM. This solution was
magnetically stirred at 1200 rpm for 3 days at room temperature.
The 100µM Aβ(1–42) stock solution in PBS was aliquoted and
frozen at −80 °C for up to 4 weeks without noticeable change
in its property. One hundred fifty microliters of pre-aggregated
Aβ(1–42) was added to 2.85 mL of Compound #11 to attain a con-
centration of 5µM Aβ(1–42) and 4µM of Compound #11. The
solution was then transferred to 5 mL vial with buffer solution and
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the fluorescence lifetime measurements were performed at room
temperature.
In vitro binding properties to amyloid plaques
In vitro experiments were conducted to characterize the binding
signal of beta-amyloid to Compound #11. The sample described
above was scanned with the device and fluorescence lifetime image
is obtained and shown in Figure 3 along with a plot of fluorescence
decay rates of unbound (green) and bound (red) Compound #11
to aggregated Aβ peptide. The in vitro fluorescence lifetime mea-
surements of Compound #11 with aggregated Aβ peptide demon-
strate that bound and unbound peptide to Compound #11 can
be resolved and differentiated with 0.85 ns difference in lifetime
and at a detection level of few 100 photons. Thus, by combin-
ing fluorescence intensity and lifetime measurements, additional
information is obtained to discriminate among several fluorescent
labels and more importantly between bound and unbound ligand
and differentiate that from natural fluorescence in the lens of the
eye.
QUANTITATIVE ANALYSIS
By knowing the signature of the fluorescent ligand, the lifetime
decay histogram can be decomposed based on multiple expo-
nential fittings and the frequency counts of photons with the
specific decay lifetime (i-photons/s) are calculated. Since the flu-
orescence decay time is a characteristic for each fluorescence
molecule, one can determine and separate the ligand from nat-
ural fluorescence of the lens that is being excited in the sample
volume. In multi-exponential model, which is the case of mixture
of fluorophores, the intensity is assumed to decay as the sum of
individual single exponential decays: I (t ) =∑ni=1 αi × e t/τi + β
; where τi is the decay time, αi is the amplitude of the compo-
nents at t = 0, and n is the number of decay times. The values
of αi and τi can be used to determine the fractional contri-
bution (ip) of each decay time. The situation where one does
not expect a limited number of discrete decay times, rather a
distribution of decay times, such behavior is expected for a mix-
ture of fluorophores. Therefore, the intensity decays are typically
FIGURE 3 | Fluorescence decay rates for bound (red) and unbound
(green) Compound #11 to Aβ peptide. Increase in fluorescence intensity
(δI∼2X) and decay rates of bound (τ=2.4 ns) Compound #11 vs. unbound
(τ=1.4 ns) to Aβ. Fluorescence lifetime image of aggregated Aβ peptide in
color coded representation.
analyzed in terms of a lifetime distribution. Thus, the αi values
are replaced by distribution function (ατ) and the component
with individual τ value is given by I (τ, t )= α(τ)e−t /τ. However,
one cannot observe these individual components with their spe-
cific lifetime τ, but only the entire decay and the total decay is
the sum of the individual decays weighted amplitudes. By anal-
ogy with the multi-exponential model, it is possible to rewrite the
amplitude associated with the ith component of distribution as
i − photons =
∫ n
0 αi (τ)τdτ∫ n
0
∑
i αi (τ)τdτ
ANIMAL STUDIES FOR SAFETY ASSESSMENTS
Animal studies were performed with the device and the ligand
[Compound #11 (0.5%), Ophthalmic Ointment] for acute toxic-
ity and photo toxicity on Dutch-belted rabbits. During the course
of the study, animals were dosed 12 times with Compound #11
Ointment (0.5%) over 4 days. Animals were examined with the
device at the beginning and end of each day. Ocular examinations
of animals treated with Compound #11 Ointment, did not present
any significant signs of ocular toxicity. Additionally, the test article
did not exhibit signs of phototoxicity.
ANIMAL STUDIES FOR PHARMACOKINETICS ASSESSMENTS
Ocular pharmacokinetic investigation of dose response via topical
administration of fluorescence ligand was performed in Dutch-
belted rabbits. The animals were anesthetized with subcutaneous
injection of Dexdomitor (0.5 mg/kg), Ketamine (5 mg/kg). A rib-
bon of Ointment approximately 1/2′′ long was then applied to the
lower right eyelid of each animal in the test group three times a
day for 4 days. Figure 4 is a plot showing the number of pho-
ton/sec indicative of Compound #11 measured in the lens nucleus
of the rabbit eye every morning after being dosed during the 4-
day study period. The measurements on the rabbits, which were
dosed with Compound #11 Ophthalmic Ointment, show signifi-
cant increase in fluorescence signal indicative of the ligand in the
nucleus of the eye along the 4-day study period. Figure 4 is a plot
of number of photons indicative of unbound ligand and shows
that after three dosages each day with 3 h separation, cumulative
fluorescence signal is detected and represent a total amount of
280 ng/mL of ligand.
FIGURE 4 | Number of photons/s indicative of unbound Compound
#11 ligand (τ=1.4 ns) in the lens of rabbit eyes along a 4-day
pharmacokinetics study.
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STUDY DESIGN AND PARTICIPANTS
The primary objective of this study was to determine the safety
of the combination system of device and fluorescent ligand. The
study was an exploratory open-label, parallel group study of five
AD subjects and five healthy volunteers, Control Group, requiring
four visits.
The study was conducted in accordance with the current revi-
sion of Declaration of Helsinki guiding physicians in medical
research involving human subjects. The New England Institutional
Review Board, Newton, MA, USA, approved the protocol to initiate
the clinical study.
A “time and events” schedule for the study is summarized in
Table A1 in Appendix. Visit 1 was a screening visit which included
several procedures with an overall objective of ensuring each
individual met the inclusion/exclusion criteria for participation
in the clinical study. Importantly, an eye exam and neurologi-
cal/psychometric evaluations were performed to qualify potential
participants against inclusion/exclusion criteria. Visit 2 included
baseline (pre-dose) measurements with the SAPPHIRE device, and
the first three doses with the Compound #11 Ointment. Visit 3
included fluorescence measurements with the SAPPHIRE device
to assess the effect of the first three doses with the Compound
#11 Ointment, administration of three additional doses and flu-
orescence scanning measurements 4 h after the last dose. A full
safety exam including an ophthalmic exam, physical exam, and
blood work were performed at the end of the day. It is important
to mention that the additional three doses during this visit did
not show any substantial changes in the results from the first three
doses in terms of safety or fluorescence measurements. Visit 4 was
a 7-day follow-up safety exam only.
Adverse events (AEs) and vital signs were monitored at each
application of ligand and at each measurement session with the
device.
INCLUSION CRITERIA
Subjects met the following inclusion criteria to participate in the
study. A Clinical Dementia Rating (CDR) score of 1 or 2 for AD
and 0 for Control group. All subjects in this study must have had
at least one intact ocular lens that has not been exposed to surgery,
trauma, or glaucoma. All subjects in both cohorts were high school
graduates.
AD subjects
Alzheimer’s disease subjects were>50 years of age, male or female.
All AD subjects met NINCDS-ADRDA criteria for Probable AD
and DSM-IV criteria for Dementia of the Alzheimer’s Type. AD
subjects did not fulfill the ICC criteria for probable DLB, the
NINDS-AIREN for probable VaD, or the Neary criteria for FTD.
All AD subjects received an MRI. In each case, the brain scans
were negative for changes associated with stroke and/or general-
ized cerebrovascular disease (e.g., the ARWMC scale). Changes
observed from MRI scans were limited to a white matter lesion
score of 0 or 1 or 2 and a basal ganglia score of 0 or 1. All subjects in
this group were high school graduates. The Protocol required that
women of childbearing potential receive pregnancy testing before
entry into the clinical trial. Of the five probable AD patients, two
were female. Both were post-menopausal, ages were 65 and 73.
Control group
The Protocol required that Control group subjects be>20 years of
age. Five normal males were enrolled in Study NEU02, age 31–77.
All healthy volunteers had no evidence of cognitive impairment
and had a Mini-Mental State Exam (MMSE) score between 28
and 30. Control group had Consortium to Establish a Registry
for Alzheimer’s Disease (CERAD) neuropsychological test battery
z-score of ≥(−1.00) for each subtest (except the MMSE which
is covered by the criteria above). Additionally, HVs had an MRI
brain scan that was judged as “normal (age appropriate)” includ-
ing ARWMC scale scores supporting the lack of cerebrovascular
disease (e.g., a white matter lesion score of 0 or 1 or 2 and a basal
ganglia score of 0 or 1) and a Sheltens scale verifying the lack of
cerebral atrophy (e.g., bilateral temporal lobe atrophy visual score
of 0 or 1). All subjects in this group of volunteers were high school
graduates.
Exclusion criteria
• History of learning or developmental disability
• History of serious active cardiac condition or significant small
vessel disease (e.g., confluent white matter alterations on struc-
tural MRI or computed tomography scan)
• History of other neurologic condition (e.g., large vessel stroke,
seizures, Parkinsonism)
• History of cataract surgery in the test eye
• History of physical injury to the test eye
• Retinal detachment
• Any lens opacity that prevents the operator from visualizing the
lens sufficiently to perform the procedure
• Pregnancy
• Nursing women
• Systemic illness that may pose an unacceptable risk to the subject
in the judgment of the investigator
Participants. Five AD subjects (two females, three males) rang-
ing from 65 to 83 years old met the NINCDS-ADRDA criteria for
Probable AD and DSM-IV criteria for Dementia of the Alzheimer’s
Type set by the CERAD. Table 1 is a list of the AD subjects recruited
for the study showing the age, sex, and test scores. The AD subjects
all had a score of 1 on the CDR scale. Also, the AD subjects had
MRI brain scan findings that do not reveal changes indicative of
stroke and/or generalized cerebrovascular disease; changes limited
to: a white matter lesion score of 0 or 1 or 2 and a basal ganglia
score of 0 or 1.
Control subjects (five males) with ages 31–77 years old were
recruited and had no evidence of cognitive impairment with a
MMSE score between 28 and 30 (Table 2). The Control subjects
Table 1 | AD subjects recruited for the study.
Subject Age MMSE CDR Total CERAD Sex
0004 65 23 1 93 F
2001 68 22 1 58 M
2002 77 23 1 53 M
2004 83 24 1 61 M
2007 73 22 1 54 F
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Table 2 | Control subjects recruited for the study.
Subject Age MMSE CDR Total CERAD Sex
0001 77 29 0 135 M
0003 58 28 0 117 M
2005 43 28 0 86 M
2006 31 29 0 85 M
2008 32 30 0 85 M
all had a CDR score of 0. Additionally, controls had an MRI brain
scan that has been judged as “normal (age appropriate)” includ-
ing ARWMC scale scores supporting the lack of cerebrovascular
disease (e.g., a white matter lesion score of 0 or 1 or 2 and a basal
ganglia score of 0 or 1) and a Sheltens scale verifying the lack of
cerebral atrophy (e.g., bilateral temporal lobe atrophy visual score
of 0 or 1).
Dose administration. A single dose consisted of a 1/2′′ rib-
bon (approximately 0.05 cc) of Compound #11 Ointment (0.5%
concentration) topically administered to the inside of the lower
eyelid with a syringe applicator. Each dose of Ointment was
applied to the study eye of the participant by a trained technician,
ophthalmologist, or nurse at the study site.
The participant was asked to keep the dosed eye closed. The
dosed eye was covered with an eye cup for 30 min after application
of each dose. Each participant in the study received all six doses of
fluorescent ligand.
Safety. Safety was evaluated by documentation of AEs, by
assessment of clinical laboratory findings, by physical examina-
tion, including measurement of vital signs, and by ophthalmic
examination.
1. Ophthalmic examinations were performed at intervals previ-
ously called-out in Protocol NEU02 (see Table A1 in Appen-
dix). Each ophthalmic examination was performed by a
Board Certified ophthalmologist who evaluated any signs and
symptoms observed vs. the subject’s baseline measures.
2. Ophthalmic exams included assessments of best spectacle
corrected visual acuity (BSCVA), uncorrected visual acuity
(UCVA), and intraocular pressure (IOP).
3. To assess the possibility that an AE had occurred, subjects
were asked at each visit if they had experienced any symp-
toms since their last examination. Questions were asked in an
“open-ended” manner, so as to solicit all inputs from subjects
regarding all potential AEs.
4. Physical examinations and clinical laboratory measures were
taken before and after each exposure to the test product. In
addition, a 7-day post study examination was conducted by
the investigator and samples collected for clinical laboratories
of both blood and urine. The results were reviewed for any
clinically significant changes.
Region of interest. According to the research conducted on
post-mortem lenses (Goldstein et al., 2003), Aβ aggregates were
reported to develop in the SN of the lens of AD patients. To locate
FIGURE 5 | A Z -Scan along the optical axis of the eye of a healthy
volunteer to identify the region of interest – the supranucleus (SN) of
the lens. Fluorescence measurements were performed at three different
locations designated as SN1, SN2 and SN3.
the ROI, i.e., the SN of the lens, an axial scan was performed along
the optical axis of the eye by displacing the objective lens with a
translation stage (Micronix, Irvine, CA, USA). By exciting natural
fluorophores, we indentify the ocular tissues in the eye and hence
the desired location in the lens of each individual. Each scan is a
two-dimensional plot of photon counts as a function of displace-
ment of the objective lens (in air). Figure 5 is an example of a
Z -Scan in the eye of a healthy volunteer showing on a logarith-
mic scale the intensity (photon counts/s) vs. displacement. The
intraocular distances can then be determined and the ROI in the
SN can be located to perform fluorescence lifetime measurements.
In this study, measurements are performed at three different loca-
tions in the SN (SN1, SN2, and SN3) to investigate the location of
the maximum fluorescent signal indicative of the bound Aβ com-
plex. The distance between each region is about 300µm and the
SN3 region is about 900µm from the lens capsule. Another illus-
tration of the Z -Scan is shown in Figure 6 overlay on an oblique
image of the anterior segments of the eye.
Once the location is known, lifetime measurements are initiated
over a scanned area (50µm× 50µm). To obtain the frequency
counts of photons (i-photons/s) with the specific decay lifetime
pertaining to the Aβ complex labeled with Compound #11.
Measurement sessions. Three different measurement sessions
with the SAPPHIRE System were performed: at Baseline, 12 and
24 h point. Each measurement consisted of a Z -Scan to determine
the ROI followed by fluorescence scanning lifetime measurements
at three different locations (three times each) within the SN of
the lens. The three locations are noted as SN1, SN2, and SN3 that
cover most of the peripheral lens region within 300µm separation
starting from the lens capsule.
After the baseline measurements with the instrument were per-
formed, the ligand was topically administered on the eye of the
recruited subjects three times at 2 h (±30 min) intervals. Same
procedure was followed at 12 h point (morning session of the next
day) and 24 h after the baseline visit.
www.frontiersin.org May 2013 | Volume 4 | Article 62 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kerbage et al. Alzheimer’s disease diagnosis in the eye
RESULTS
SAFETY
This initial safety study was designed to assess risks associated with
the use of the system in normal subjects (Controls) and Probable
AD patients over a period of time that is the same as will be utilized
in future trials. Overall, no serious AEs were observed. The SAP-
PHIRE System, device and the Ophthalmic Ointment, used in this
study posed no substantial safety risk. During the course of this
study, subjects were administered three applications of Ointment
over 4 h period on Visit 2 of the clinical study and, on the next day,
administered three additional doses of Ointment over a period of
4 h to the study eye only. The study eye only was illuminated with
the device (Class I laser) three times over a 2-day period. Compre-
hensive ophthalmic examinations were conducted at three time
points: before application of the Compound #11 Ointment, after
FIGURE 6 | Overlay of a Z -Scan on an oblique image of a healthy
volunteer.
application of each of the treatments with Compound #11 Oint-
ment and employment of the device at Visit 2 and Visit 3. None
of the subjects were discontinued from the study for any reason.
There were no significant changes in UCVA and BSCVA. Slit lamp
biomicroscopy was also performed as a part of the study, along
with an ophthalmoscopic examination and the findings were unre-
markable as compared between pre-treatment, post-treatment,
and follow-up values. No remarkable observations were made by
either slit lamp biomicroscopy or from ophthalmoscopy.
Observations of the dilated fundus showed no significant
changes during the course of this Safety Study. Dilated fundus
examination was completed using an ophthalmoscope to view the
inner structures of the eye and included cup to disk ratio, changes
in the retinal pigment epithelium and the presence of a nevus,
if present, was documented, along with any other abnormalities.
After the completion of the trial there were no clinically significant
changes that could be attributed to this procedure
EFFICACY
Fluorescence lifetime measurements were performed at three dif-
ferent locations starting from the lens cortex (SN1) into deeper
SN region (SN3). As previously stated herein, SN3 is the area
that corresponds to the SN of the lens and is about 900µm from
the lens capsule. Figure 7 shows plots of the frequency counts
(i-photons/s) of the fluorescence lifetime specific of the bound
Compound #11 to Aβ detected for each individual in the two
treatment groups of this study.
In both groups, the measurements in the deeper SN region
(SN3) show larger signal increase over the other regions (SN1 and
SN2). The region is about 900µm deep from the lens capsule.
However, this difference is significantly greater in the “AD Patient”
group. In addition, it is interesting to observe that SN3 measure-
ments for Controls are less than half that of AD patient SN3
measurements. Fluorescent intensity measurements in the SN1
and SN2 areas are also higher among AD patients as compared to
normal subjects.
FIGURE 7 | Plots of i -photons/s at 12 h point for (A) AD patients and (B) controls showing all three different locations (SN1, SN2, and SN3).
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FIGURE 8 | Plot of maximum i -photon/s measured at anyone location. Table represents the data points for the two groups and their corresponding
averages.
The max signal (or frequency count) for each participant, pre-
sented in the figure above, is shown more clearly in Figure 8.
Overall,Aβ specific frequency counts measured from the AD group
are more than twofold higher than corresponding measures in
the Control’s group (Table in Figure 8). There is clear separation
between the AD patients and Control groups. It is important to
mention a few observation points about the results. In particular,
Subject 0001 is a normal individual as determined by cognitive
testing; however, fluorescent measurements from this individual
are higher than from other Control subjects in the cohort, which
could be interpreted as a false positive. This patient is a 78-year-
old individual with Apolipoprotein E4 variant (ApoE4), known
for the genetic risk factor for AD, positive test. There is evidence
that Aβ aggregation starts to occur years before symptoms arise.
The ApoE4 positive status of this participant increases his risk
of developing AD in the future. Patient 2001, on the other hand,
had a negative reading with device during which head movements
and eye motion interfered with test conduct. It is possible that
the movement during the session affected the positioning of the
measurements in the eye, and that the exact location in the SN was
missed and resulted in low signal.
DISCUSSION
To the best of our knowledge, this is the first time a clinical
study is conducted to detect an exogenous fluorescent signature
bound to Aβ in the lens of human being. The clinical study was
conducted with no serious AEs related to the use of the fluo-
rescent ligand, Compound #11, or the laser scanning device in
the eye. In addition to the safety outcome of this small study,
the results obtained from the SAPPHIRE System were encour-
aging in terms of bioavailability of the ligand in the anterior
segment of the eye and the sensitivity of the device to differ-
entiate between the AD and the Control groups. The average
signal detected of the AD patients was approximately twice that
of Control group. The deeper supranuclear region reveals higher
signal as compared to other regions in the SN. The results
complement the previous studies by Goldstein et al. (2003) to
detect the presence of Aβ in the supranuclear region in lens
samples from AD patients. Several techniques were used to ana-
lyze Aβ in lens samples including Congo Red staining, west-
ern blot, tryptic-digest/mass spectrometry electrospray ionization,
and anti-A surface-enhanced laser desorption ionization mass
spectrometry, immunohistochemistry, and immunogold electron
microscopy that showed a complete or partial circumferential
deposit of protein aggregates in the SN. Control lenses from
individuals with no evidence of AD, including controls from
patients with other neurodegenerative diseases, showed no such
deposits.
Moreover, a recent study by Michael et al. (2012) performed on
post-mortem lens samples from AD patients located cortical opac-
ities similar to the supranuclear cataracts described by Goldstein
et al. (2003). However, the authors were unable to detect Aβ in the
lens using amyloidopholic staining methods. The contradictory
findings between Goldstein et al. (2003) and Michael et al. (2012)
might be due to differences in staining methods of lens samples.
These in vitro experiments emphasize the importance of in vivo
studies in the human lens to determine the Aβ presence in AD
patients.
The data in this study represent a small population and further
investigational clinical studies are underway to include a larger
number of participants for statistical analysis and establishment
of the SAPPHIRE System as a probable tool to diagnose AD at an
early stage.
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APPENDIX
Table A1 |Time and events schedule for the study.
Visit 1 Visit 2 (PM) Visit 3 (AM) Visit 3 (PM) Visit 4
Baseline SAPPHIRE II Dose (3×) SAPPHIRE II Dose (3×) SAPPHIRE II Follow-up
exam
(−0 to−21 days)
prior to Visit 2
2 h (±30 min)
apart
Next day after
Visit 2 before dosing
2 h (±30 min)
apart
4 h (±30 min)
post-final dose
(7±2 days)
after Visit 3
SAPPHIRE II
measurements
X 8(+/−1hr)AM X
Fluorescent
ligand dosing
5(+/−1hr)PM start X
Informed consent X
Demographic
information
X
Inclusion/exclusion
criteria
X
Cognitive
assessments
X
Medical history X
Physical
examination
X X
ECG X X
Ophthalmology
exam
X X X
Vital signs X X X X X
Clinical
laboratories
X* X X*
Adverse events X X X X X
Concomitant
medications
X X X
*Including serum pregnancy test for women of childbearing potential.
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